JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 131 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $451,308 | -15.7% | 243,950 | -49.4% | 0.08% | -28.8% |
| Q4 2022 | $535,520 | +79.7% | 482,450 | +278.9% | 0.12% | +63.9% |
| Q3 2022 | $298,000 | -45.2% | 127,331 | -29.1% | 0.07% | -43.3% |
| Q2 2022 | $544,000 | -68.3% | 179,531 | -29.0% | 0.13% | -61.9% |
| Q1 2022 | $1,717,000 | -35.0% | 252,831 | -20.0% | 0.33% | -25.7% |
| Q4 2021 | $2,640,000 | +25.9% | 316,175 | +12.0% | 0.45% | +17.6% |
| Q3 2021 | $2,097,000 | +1755.8% | 282,250 | +1600.3% | 0.38% | +1714.3% |
| Q2 2021 | $113,000 | -43.8% | 16,600 | -15.3% | 0.02% | -47.5% |
| Q1 2021 | $201,000 | – | 19,600 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |